Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis

Luigi Cavanna _, Chiara Citterio and Elena Orlandi

PDF  |  Full Text  |  How to cite

Oncotarget. 2019; 10:209-215. https://doi.org/10.18632/oncotarget.26541

Metrics: PDF 2526 views  |   Full Text 3033 views  |   ?  


Luigi Cavanna1, Chiara Citterio1 and Elena Orlandi1

1Oncology and Hematology Department, Oncology Unit, Piacenza General Hospital, Piacenza, Italy

Correspondence to:

Luigi Cavanna, email: [email protected]

Keywords: immuno-oncology; immunotherapy; NSCLC; EGFR mutation; chemotherapy

Received: November 08, 2018     Accepted: December 10, 2018     Published: January 04, 2019


Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) mutation benefit from a first line of treatment with tyrosine kinase inhibitors (TKIs). After progression, the choice of treatment is between chemotherapy and immune checkpoint inhibitors, but the role of EGFR mutation in the response to immunotherapy is still unclear. A network meta-analysis was performed and 4 randomized trials comparing immune checkpoint inhibitors versus chemotherapy were identified. A Bayesian network meta-analysis was carried out to compare three checkpoint inhibitors (nivolumab, pembrolizumab and atezolizumab) versus chemotherapy (docetaxel), evaluating their Hazard Ratio (HR) and 95% Confidence Interval (CI) for Overall Survival (OS). Results suggest that patients with NSCLC and EGFR mutation, previously treated with TKIs, show better OS when treated with docetaxel in comparison to checkpoint inhibitors treatment.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26541